Clinical trials recruiting for Atopic dermatitis
126
Recruiting trials
40
US states with sites
47
Countries
25%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Dupilumab | 13 |
| Abrocitinib | 6 |
| Upadacitinib | 3 |
| BBT001 | 2 |
| Baricitinib | 2 |
| IBI3002 | 2 |
| Lebrikizumab | 2 |
| Ruxolitinib Cream | 2 |
| Tralokinumab | 2 |
| 1.5% QLM3003 ointment | 1 |
| 2% QLM3003 ointment | 1 |
| APG777 | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 29 |
| Florida | 17 |
| Michigan | 15 |
| New York | 15 |
| Texas | 15 |
| Maryland | 13 |
| Pennsylvania | 13 |
| Illinois | 10 |
| South Carolina | 10 |
| Georgia | 9 |
| Alabama | 8 |
| Indiana | 8 |
Top cities
New York, New York 12Los Angeles, California 11Miami, Florida 9Birmingham, Alabama 8Dallas, Texas 8Philadelphia, Pennsylvania 8Sacramento, California 8San Diego, California 8Indianapolis, Indiana 7San Antonio, Texas 7
Self-screener
Recruiting trials
- A Clinical Study to Evaluate SM17 for Atopic Dermatitis
- A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
- A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
- A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
- A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
- A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
- A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
- A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
- A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
- A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
- A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants
- A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis
- A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis
- A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
- A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
- A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis
- A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
- A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
- A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment
- A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- AI App for Management of Atopic Dermatitis
- An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
- An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
- An Observational Study of Patients With Dermatologic Disease
- Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive Skin.
- BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis
- Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- Cardamom and Topical Roseomonas in Atopic Dermatitis
- Changes in Skin Myco- and Microbiome After Lebrikizumab Treatment
- Characterisation of Skin Microstructure Under Normal and Atrophied States
- Characterization of Chronic Hand Eczema
- Clinical-Instrumental Study To Evaluate And Compare The Efficacy And Tolerability Of Two Emollients Products In Atopic Dermatitis
- Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
- CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness
- CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry
- Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies
- DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
- Deployment o the Multidisciplinary Prospective Cohort Imminent
- Determinants of Chronic Inflammatory Skin Disease Trajectories
- Dietary Intervention on Atopy
- Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis
- Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis
- Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults
- Drug Survival of Target Therapies in Atopic Dermatitis
- Dupilumab De-escalation in Pediatric Atopic Dermatitis
- Dupixent and Narrowband UVB for Atopic Dermatitis
- Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.
- Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
- Ethnic Differences in Mechanisms of Action of Dupilumab
- Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
- Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
- Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study
- Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
- Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation
- FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
- Frequency of Palpebral Involvement in Adult With Atopic Dermatitis
- HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
- Herbal Ointment in Treating Atopic Dermatitis Topically
- IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients
- ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
- Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
- Lebrikizumab in Moderate-to-severe Atopic Dermatitis
- Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
- Meditation in Inflammatory Dermatosis
- Metabolic Profiling of Immune Responses in Immune-mediated Diseases
- Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
- Microbiome in Atopic Dermatitis Under Systemic Therapy
- Mind and Skin - the Neurocutaneous Axis in Atopic Eczema
- Molecular Signatures in Inflammatory Skin Disease
- Molecular Signatures of Cutaneous Dupilumab Response
- Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
- Multi-modal Quantitative Imaging of the Skin
- National Register of Moderate and Severe Adult Atopic Dermatitis
- Nationwide Research on the Rewilding of Kindergarten Yards
- Natural History and Genetics of Food Allergy and Related Conditions
- Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction
- Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.
- PALLAS Laser for Skin Diseases
- Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
- Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
- Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis
- Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Prospective Longitudinal Observational Research in Atopic Dermatitis
Related conditions
Trials recruiting for Atopic dermatitis often also study these conditions. Each links to its own recruiting-trial list.
Eczema 196Psoriasis 233Hidradenitis Suppurativa 7Eczema, Atopic 5Atopic Dermatitis Eczema 12Lupus 332Asthma 382Alopecia Areata 4Skin Diseases 5Pregnancy Related 28
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Atopic dermatitis trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.